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ABSTRACT  
 
Rationale: A hallmark of type 2 diabetes is insulin resistance, which leads to increased endothelial cell 
production of superoxide and a simultaneous reduction in availability of the vasoprotective signalling 
radical, nitric oxide (NO). We recently demonstrated in preclinical models that type 2 diabetes 
simultaneously causes resistance to insulin like growth factor-1 (IGF-1) mediated glucose lowering and 
endothelial NO release.  
 
Objective: To examine the effect of insulin and IGF-1 resistance specifically in endothelial cells in vivo. 
 
Methods and Results: We generated mice expressing mutant IGF-1 receptors (mIGF-1R), which form 
non-functioning hybrid receptors with native insulin receptors (IR) and IGF-1R, directed to endothelial 
cells under control of the Tie2 promoter-enhancer. Despite endothelial cell insulin and IGF-1 resistance, 
mutant IGF-1R endothelial cell over-expressing mice (mIGFREO) had enhanced insulin and IGF-1 
mediated systemic glucose disposal, lower fasting free fatty acids and triglycerides. In hyperinsulinaemic-
euglycaemic clamp studies, mIGFREO had increased glucose disposal and increased glucose uptake into 
muscle and fat, in response to insulin. mIGFREO had increased NADPH oxidase 4 (Nox4) expression 
due to reduced expression of the microRNA, miR-25. Consistent with increased Nox4, mIGFREO 
endothelial cells generated increased hydrogen peroxide (H2O2), with no increase in superoxide. 
Treatment with catalase, a H2O2 dismutase restored insulin tolerance to wild type levels in mIGFREO. 
  
Conclusion: Combined insulin and IGF-1 resistance restricted to the endothelium leads to a potentially 
favourable adaptation in contrast to pure insulin resistance, with increased Nox4-derived H2O2 generation 
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Nonstandard Abbreviations and Acronyms: 
 
TG  transgenic 
SVEC  saphenous vein endothelial cells 
PTPs  Phospho-tyrosine phosphatases 
PKC  Protein kinase C 
PEC  pulmonary endothelial cells 
NOX 2/4 NADPH oxidase 2/4 
NO  Nitric oxide 
mIR-25  microRNA-25 
mIGF-1R mouse IGF-1 receptor 
L-NMMA L-NG-monomethyl Arginine citrate 
IR/IGF-1R heterodimers of insulin receptor and IGF-1 receptor 
IR  Insulin receptor 
IGF-1  insulin-like growth factor-1 
hIGF-1R human IGF-1 receptor 
HFD  High fat diet 
GPrx  Glutathione peroxidase 
ERK  MAP kinase 1/2 
EndoRa endogenous glucose production 
ECs  Endothelial cells 






A hallmark of type 2 diabetes mellitus is insulin resistance, defined as an inability of insulin to 
activate its complex intracellular signalling network appropriately (1). In addition to regulating glucose 
homeostasis, insulin activates the enzyme endothelial nitric oxide (NO) synthase (eNOS) in endothelial 
cells to stimulate generation of the signalling radical, NO (2,3). Acting via its tyrosine kinase receptor, 
which is structurally homologous to the insulin receptor (IR), insulin like growth factor-1 (IGF-1) also 
regulates metabolic and cellular responses to nutrient availability (4) and at the same time may stimulate 
eNOS in endothelial cells to generate NO (5). 
 
We have shown that insulin resistance specific to the endothelium induced by a range of different 
mechanisms, leads to reduced availability of NO and generation of excess concentrations of the free 
radical superoxide, the principal enzymatic source of which is the Nox2 isoform of NADPH oxidase (6–
9). However, we have also shown that diet-induced obesity leads to excess generation of the oxidant and 
dismutation product of superoxide, hydrogen peroxide (H2O2) (10). Moreover, we showed that diet-
induced obesity leads to resistance to both insulin- and IGF-1 mediated glucose lowering and serine 
phosphorylation-mediated activation of eNOS (5). In order to improve our understanding of the 
synergistic impact of insulin and IGF-1 signalling in the endothelium, we generated a transgenic mouse 
expressing a mutant IGF-1 receptor (mIGF-1R), which forms non-functioning hybrid receptors with 
native insulin receptors and IGF-1R specifically in the endothelium (herewith described as: mIGFREO). 
When expressed exclusively in muscle, mIGF-1R induces resistance to both insulin and IGF-1 (11). Here, 
we describe for the first time the effect of endothelium-restricted insulin and IGF-1 resistance, secondary 
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Endothelial cells from patients with type 2 diabetes are resistant to both insulin and IGF-1 mediated 
eNOS phosphorylation.  
 
Patients with and without diabetes mellitus undergoing coronary bypass surgery were recruited. 
Total and serine phosphorylated eNOS and Akt in saphenous vein endothelial cells (SVEC) were 
quantified using Western blot under basal conditions and after stimulation ith insulin or IGF-1. Basal 
eNOS and AKT was similar in SVEC from patients with and without type 2 diabetes mellitus (Figure 
1A&B). Basal serine phosphorylated eNOS was similar in SVEC from patients with or without type 2 
diabetes, as was basal serine phosphorylated Akt (Figure 1C&D). As we demonstrated in preclinical 
models (5), insulin and IGF-1 stimulated eNOS phosphorylation were blunted in SVEC from patients 
suffering from type 2 diabetes, compared to patients without type 2 diabetes (Figure 1E&G). Insulin and 
IGF-1 stimulated Akt phosphorylation were similar when comparing SVEC from patients with and 
without type 2 diabetes mellitus (Figure 1F&G). There was lower Nox4 expression in SVEC from 
patients with type 2 diabetes compared to patients without type 2 diabetes, whereas Nox2 protein levels 
were increased in SVEC from patients with type 2 diabetes compared to patients without diabetes (Figure 
1H&I). Superoxide generation was higher in SVEC from patients with diabetes (Figure 1J). 
 
Generation and characterisation of transgenic mice with endothelial specific expression of mutant IGF-1 
receptors.  
 
To examine the effect of disrupting both insulin and IGF-1 signalling in the endothelium, we 
generated a novel transgenic mouse expressing a human IGF-1R with an amino acid substitution in the 
ATPase domain (11) directed to the endothelium under control of the Tie2 promoter-enhancer (Online 
Figure IA-C). Mutant IGF-1R endothelium over-expressing mice (described, as mIGFREO), were born 
with the same frequency as their wild type (WT) littermates (data not shown). There was no difference in 
body weight, organ weight, fat pad size or blood pressure between mIGFREO and their WT littermates 
(Figure 2A&B and Online Figure ID&E). We, next quantified the levels of human and native (mouse) 
IGF-1R mRNA expression in whole organs and pulmonary endothelial cells (PEC). While human IGF-1R 
mRNA was detected only in mIGFREO aorta and lungs (Figure 2C), native (mouse IGF-1R) mRNA was 
similar in both mIGFREO and WT aorta and lung (Online Figure IF). There was no human IGF-1R 
mRNA detectable in PEC from WT mice or non-endothelial cells from mIGFREO (Figure 2D), and there 
was almost no detectable expression of hIGF-1R in monocytes from mIGFREO (Online Figure IG). 
Human IGF-1R mRNA was not detected in pancreatic islets, pericytes or endothelium denuded aorta of 
mIGFREO mouse showing the specificity of the Tie-2 promoter in mIGFREO (Online Figure IH).  
Western blot analysis confirmed that total IGF-1R protein levels were significantly increased in 
mIGFREO endothelial cells compared to WT littermates, as were IR/IGF-1R heterodimers (hybrid 
receptors) (Figure 2E&F). Hybrid receptors in mIGFREO cells were resistant to insulin, as expected (12), 
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Disrupted insulin and IGF-1 signaling in mIGFREO endothelial cells.  
 
There was no difference in total eNOS, total Akt or phosphorylated Akt during standard culture 
conditions in mIGFREO PEC compared to WT littermates (Figure 3A-D). Serine phosphorylated eNOS 
was significantly reduced in mIGFREO endothelial cells compared to WT littermates (Figure 3E). Basal 
and insulin-induced phosphorylation at Tyr657, an important residue in the negative regulation of eNOS 
was not significantly different between WT and mIGREO PEC (Online Figure IIA). While, as seen in 
humans with type 2 diabetes, mIGFREO PEC had reduced serine phosphorylation of eNOS in response to 
insulin and IGF-1, insulin-stimulated Akt phosphorylation was preserved (Figure 4A-C). Radioactive 
eNOS activity assay and phosphorylation of eNOS analysis of whole aorta also showed that mIGFREO 
endothelial cells were resistant to insulin and IGF-1 stimulation (Figure 4D&E and Online Figure IIB). 
We, therefore examined the possibility that eNOS and Akt demonstrate differential sensitivities to insulin-
mediated serine phosphorylation in endothelial cells.  We observed that in WT PEC, while AKT 
phosphorylation was induced on exposure to 50 nmol/L insulin, significant eNOS phosphorylation 
required a substantially higher concentration (150nmol/L) (Figure 4F&G). Similarly in insulin-resistant 
PEC from mIGFREO mice, although AKT phosphorylation was induced with 50 nmol/L insulin, eNOS 
was relatively resistant to phosphorylation at 150 nmol/L (Figure 4H). Next, we probed ERK and PKC - 
two key molecules involved in insulin signalling in endothelial cells. While we did not observe any 
difference in insulin-induced ERK phosphorylation between WT and mIGFREO PEC, PKC activity in 
response to insulin stimulation was reduced in mIGFREO PEC compared to WT cells (Online Figure 
IIC&D). 
 
mIGFREO mice have normal glucose tolerance but enhanced glucose lowering in response to systemic 
insulin or IGF-1.  
 
mIGFREO had similar fasting and fed capillary blood glucose, fasting and fed serum insulin, and 
random serum IGF-1 concentrations to WT littermates (Figure 5A&B and Online Figure IIIA). 
mIGFREO also had similar glucose tolerance as WT littermates, but had enhanced glucose disposal in 
insulin and IGF-1 tolerance tests compared to WT littermates (Figure 5C-G). It has been suggested, that 
by increasing delivery of glucose to its target tissues, insulin-induced vasodilation of small arteries is 
important for glucose uptake (13). In light of the enhanced insulin sensitivity at a whole-body level seen 
in mIGFREO, we examined insulin-induced relaxation in 2nd order mesenteric arteries. Consistent with 
the increased insulin-mediated glucose uptake seen in a range of tissues we observed an increase in 
insulin-induced vasorelaxation of 2nd order mesenteric arteries from mIGFREO (Figure 5H&I and Online 
Figure IIIB). Consistent with enhanced insulin sensitivity, fasting free fatty acids and triglycerides were 
significantly lower in mIGFREO compared to WT littermates (Figure 5J&K). Serum concentrations of 
the adipokines leptin and adiponectin were not different between mIGFREO and WT controls (Online 
Figure IIIC&D). In low-dose hyperinsulinaemic euglycaemic clamp studies, mIGFREO blood glucose 
was maintained throughout the clamp, glucose infusion rate was higher in mIGFREO, consistent with 
increased insulin sensitivity (Figure 6A&B). Fasting (basal) glucose turnover was no different between 
groups (Online Figure IVA). However, consistent with enhanced insulin sensitivity, the rate of glucose 
disappearance (Rd) was significantly higher in mIGFREO (Figure 6C). Endogenous glucose production 
(EndoRa) was no different between groups, indicative of no difference in hepatic gluconeogenesis 
(Online Figure IVB). In tracer studies, glucose uptake into brown adipose tissue, as well as skeletal 
muscle, was significantly increased in mIGFREO (Figure 6D-F and Online Figure IVC). Consistent with 
increased insulin sensitivity, in vivo insulin stimulation led to greater tyrosine phosphorylation of IR in 





























    
    















DOI: 10.1161/CIRCRESAHA.121.319517   6 
 
Increased vascular H2O2 in mIGFREO.  
 
Aortic rings from mIGFREO mice had similar responses to the endothelium- and NO-dependent 
vasodilator acetylcholine (Online Figure VA), and the endothelium-independent vasodilator sodium 
nitroprusside, compared with WT littermates (Online Figure VIA). Vasoconstriction to phenylephrine 
remained unchanged in mIGFREO compared to their WT littermates (Online Figure VB). Bioavailable 
NO in response to isometric tension, assessed by measuring the constrictor response to the NOS inhibitor 
L-NMMA, was no different in mIGFREO compared to WT littermates (Online Figure VC). To examine 
the possibility that H2O2 generation may contribute to the vasorelaxation response to acetylcholine in 
mIGFREO, as we previously demonstrated in obese mice (10), we treated rings with the H2O2 dismutase, 
catalase (Online Figure VD&E). There was no difference in logEC50 of acetylcholine responses between 
mIGFREO and WT littermates after catalase treatment (note logarithmic scale; Online Figure VF). 
However, percent change in maximum relaxation was significantly increased in mIGFREO aorta 
compared to WT littermates (Online Figure VG) demonstrating increased hydrogen peroxide release in 
Ach-induced vasorelaxation in mIGFREO mice. Next to test whether inhibiting catalase can reverse 
catalase-induced reduction of ACh-induced relaxations in aorta, we performed vasorelaxation studies with 
the catalase inhibitor (3-amino-1,2,4-triazole) in the presence of catalase. The data confirmed the 
significance of catalase inhibitable H2O2 in Ach-induced relaxation in mIGFREO aorta (Online Figure 
VH). To confirm increased H2O2 production in mIGFREO aortic rings, we examined the amount of 
catalase-inhibited aortic H2O2 production using Amplex Red assay. mIGFREO aorta had significantly 
higher concentrations of H2O2 compared to WT littermates (Online Figure VI). We quantified superoxide 
generation in endothelial cells from mIGFREO using NADPH-dependent chemiluminescence and found 
no difference in superoxide generation between mIGFREO and WT littermates (Online Figure VJ).  
 
Excessive endothelial H2O2 leads to enhanced whole-body insulin sensitivity.  
 
H2O2 has previously been described as an insulin sensitizer in skeletal muscle and we too found 
that it can increase glucose uptake in muscle cells in culture in a dose-dependent manner (data not 
shown). Hence, we examined the effect of H2O2 quenching on insulin sensitivity in vivo in mIGFREO 
mice. Chronic treatment with catalase restor d insulin sensitivity in mIGFREO to WT levels in insulin 
tolerance testing (Figure 7A-C). Moreover, catalase treatment reduced levels of tyrosine phosphorylated 
insulin receptor in mIGFREO liver (Figure 7D). Nox4 has been described as the primary source of H2O2 
in endothelial cells. On the other hand, the related Nox isoform Nox2 is predominately responsible for 
superoxide generation. Nox2 mRNA expression in endothelial cells from mIGFREO was similar to WT 
littermates, whereas Nox4 mRNA was significantly higher in mIGFREO (Figure 7E&F). Endothelial cell 
Nox2 protein expression was lower in mIGFREO compared to WT littermates, whereas and consistent 
with mRNA expression, Nox4 protein expression was higher in mIGFREO compared to WT littermates 
(Figure 7G&H). No other ROS-related gene expression was changed in mIGFREO PEC (Online Figure 
VIB). To dissect how endothelial insulin and IGF-1 resistance contributes to whole body insulin 
sensitivity in the pathological context of diet-induced insulin resistance, we fed mIGFREO and WT 
littermates a high fat diet (HFD) for 10 days. We have previously shown that short term HFD feeding can 
result in resistance to insulin-induced glucose lowering before it causes insulin resistance in the 
endothelium (10,12). There was no significant difference in changes in body weight before and after HFD 
(Online Figure VIIA) or fasting glucose levels (Online Figure VIIB) between mIGFREO and WT animals 
upon HFD feeding. mIGFREO mice fed HFD, despite insulin resistance at the level of the endothelium, 
did not develop glucose intolerance compared to WT littermates (Online Figure VIIC&E). However, 
detailed exploratory GTT analysis at 30 minutes showed that glucose levels trended to be lower in 
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Mutant IGF-1R regulates Nox4 expression through miR-25 in endothelial cells from mIGFREO and 
patients with type 2 diabetes.  
 
Unlike other Nox isoforms, Nox4 activity is dependent primarily on its abundance. Whilst 
transcriptional regulation of Nox4 is incompletely understood, a number of regulators of Nox4 
expression, both negative and positive, have been proposed (14). One such transcriptional regulator is the 
microRNA mIR-25, which has been suggested to be a negative regulator of Nox4 transcription. We 
measured mIR-25 level in aorta and PEC of mIGFREO mice and found it was significantly reduced 
compared to WT littermates (Figure 8A&B). Moreover, miR-25 level was higher in SVEC of patients 
with diabetes (Figure 8C) and, importantly, when we transfected SVEC from patients without diabetes 
with mutant IGF-1R, miR-25 expression was significantly reduced with a reciprocal increase in Nox4 
expression (Figure 8D-E). Finally, we used a synthetic miR-25 mimetic to elevate its level directly in 
SVEC and found it significantly decreased mRNA expression of Nox4 (Figure 8F). Taken together, these 
results show that disrupting IGF-1R and IR signalling by mutant IGF-1R expression leads to increased 







Lower-order organisms have a single receptor (DAF-2) that transmits external cues to regulate 
glucose homeostasis, metabolism and growth (15), whereas mammals have evolved to have 2 separate 
receptors that regulate glucose homeostasis (the insulin receptor) and growth (the IGF-1 receptor). Insulin 
may act in synergy with IGF-1 to coordinate responses to nutrient availability. An unexplained paradox 
exists whereby, in worms and flies downregulation of DAF-2 has an advantageous effect on health, 
leading to stress resistance and extended lifespan (15), whereas in humans insulin resistance leads to a 
range of chronic disorders of health. To date, no studies have examined the effect of the combination of 
diminished insulin and IGF-1 actions in vascular cells on metabolic and vascular homeostasis in 
mammals. To examine the effect of the combination of prolonged and selective insulin and IGF-1 
resistance at the level of the endothelium, we generated a transgenic mouse expressing mutant IGF-1R 
that form non-functioning hybrid receptors with native insulin receptors and IGF-1R, specifically in 
endothelial cells.  
 
The following novel findings are reported: 1) Endothelial cells from humans with advanced 
atherosclerosis and type 2 diabetes are resistant to both insulin- and IGF-1-mediated eNOS activation. 2) 
Endothelial cell-specific expression of mutant IGF-1R leads to resistance to insulin- and IGF1-mediated 
eNOS serine phosphorylation in endothelial cells. 3) Despite this, mIGFREO have enhanced glucose 
disposal in response to systemic insulin and IGF-1. 4) In contrast to mice with endothelial cell-specific 
insulin resistance (7,8), mIGFREO have reduced Nox2 NADPH oxidase expression and increased Nox4 
NADPH oxidase expression at an mRNA and protein level. 5) Catalase, which reduces H2O2, restores 
insulin-mediated glucose lowering to WT levels in mIGFREO. 6) mIGFREO mice reveal the microRNA 
miR-25 as an important regulator of Nox4 expression, this was recapitulated in endothelial cells from 
humans with type 2 diabetes and accelerated atherosclerosis.  
 
Endothelial cells from humans with advanced atherosclerosis and type 2 diabetes are resistant to 
both insulin- and IGF-1-mediated eNOS serine phosphorylation.  
 
As proof of principle, we examined the responses of saphenous vein endothelial cells (SVEC) 
from patients undergoing aortocoronary bypass surgery to insulin and IGF-1. We showed that, consistent 
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blunted serine phosphorylation of eNOS in response to both insulin and IGF-1. We also demonstrated 
decreased Nox4 NADPH oxidase expression and increased Nox2 expression. This is, perhaps not 
surprising when one considers that SVEC from patients with type 2 diabetes have been exposed to 
multiple systemic factors which are not present in mIGFREO (which have increased Nox4 and reduced 
Nox2 expression in EC) including, but not limited to; hyperglycaemia, hyperlipidaemia, hyperinsulinemia 
and excess circulating cytokines. This notwithstanding, we demonstrate here for the first time that type 2 
diabetes in humans is accompanied by both insulin and IGF-1 resistance at the level of the endothelium, 
providing a conceptual framework for the present study.  
 
Obesity leads to resistance to insulin and IGF-1 in the endothelium. 
 
 Obesity and type 2 diabetes mellitus induce defects at multiple points in the insulin signalling 
pathway, resulting in resistance to insulin-mediated glucose uptake into skeletal muscle and other insulin 
target tissues (1). We have shown that whole-body genetic (7) and diet-induced insulin resistance (5,10) 
also lead to insulin resistance at the level of the endothelium. During the development of obesity and 
simultaneous insulin resistance, we have also demonstrated a similar decline in IGF-1 actions at a whole-
body level (5,16), and within the endothelium (5). Whilst we have a deep understanding of the effects of 
whole body and endothelial cell-specific insulin resistance on NO availability (6–9,17), the local and 
systemic consequences of prolonged insulin and IGF-1 resistance in the endothelium are unexplored. 
Moreover, the effects of endothelium-restricted insulin and IGF-1 resi tance on systemic glucose 
homeostasis remain unclear. 
 
mIGFREO mice reveal differential sensitivity of Akt and eNOS to insulin-mediated serine 
phosphorylation in endothelial cells.  
 
Akt is a critical node (18) in the downstream insulin signalling pathway which lies proximal to 
eNOS. In endothelial cells from humans with advanced atherosclerosis and type 2 diabetes, we showed 
that at 100nM insulin-induced Akt phosphorylation was preserved, whereas eNOS phosphorylation was 
blunted. This scenario was recapitulated in mIGFREO mice. The role of Akt in insulin signalling in the 
endothelium in health and disease is of particular interest to the field. Elegant studies in adipocytes from 
the Accilli laboratory (19), raised the possibility that activation of different nodes in the insulin signalling 
pathway downstream of the insulin receptor require different concentrations of insulin, differing by as 
much as tenfold to phosphorylate the protein sufficiently. This has not been examined in endothelial cells 
from insulin sensitive or insulin resistant mammals. We, therefore examined the effect of different 
concentrations of insulin on Akt and eNOS phosphorylation in endothelial cells from mIGFREO mice 
and their WT littermates. Interestingly, we found that Akt was more sensitive to insulin than eNOS with a 
significant increase in phosphorylated Akt occurring at 50nM, which did not lead to an increase in serine 
phosphorylated eNOS in WT or mIGFREO. These data are important to our understanding of insulin 
signalling in the endothelium in health and disease. The contrast between blunted insulin-induced eNOS 
activation seen in endothelial cells from mIGFREO and the enhanced responses in resistance vessels most 
likely reflects the different mediators of relaxation in large and small arteries (20). Whereas NO has been 
shown to be most important in insulin-induced relaxation in large arteries (8), an endothelium derived 
hyperpolarising factor (EDHF) has been shown to be the principal mediator of insulin-induced relaxation 
of small arteries (21). Our data demonstrating increased release of H2O2, a putative EDHF, from 
mIGFREO in response to insulin fits with the enhanced relaxation seen in 2nd order mesenteric arteries 
from mIGFREO. 
 
Insulin resistance in the endothelium and glucose intolerance.  
 
Insulin signalling in the endothelium has been suggested to be important in glucose uptake into 
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insulin signaling regulates glucose transport and metabolism in endothelial cells. It has been shown that 
insulin signaling does not regulate glucose transport in human micro- and macrovascular endothelial cells 
(23), bovine brain and retinal endothelial cells (24,25), whereas glucose transport and glycogen synthesis 
are increased by insulin in bovine endothelial cells isolated from adipose tissue or retinas and rabbit ECs 
(26–28). Consistent with the mIGFREO phenotype we have described here, seminal in vivo studies from 
Vicent et al demonstrate that mice with endothelial cell depletion of IR display no changes in fed and 
fasting blood glucose levels and in fact, at 6 months of age have better glucose tolerance than WT 
littermates; suggesting that normal glucose uptake is not dependent on insulin signaling in endothelial 
cells (29). These data suggest that the presence of endothelial insulin and IGF-1 resistance may represent 
a potentially favourable adaptation to metabolic stress, leading to enhanced glucose uptake in response to 
insulin and a favourable effect on lipid profile.  
 
Reactive oxygen species as signalling molecules in glucose homeostasis.  
 
Some biomolecules may be modified by oxidation (30). Once specific types of oxidant are 
generated at a given time and place, they can mediate reversible and irreversible modifications in a range 
of molecules. In relation to insulin signalling, it is thought that inhibition of phosphotyrosine 
phosphatases (PTPs) by H2O2-mediated oxidation of cysteine residues is necessary for optimal signalling 
(31–34). It has also been shown that mild oxidative conditions enhance the activation of IGF-1R (35), 
suggesting that optimal insulin and IGF-1R responsiveness involves redox priming. Mice deficient in 
glutathione peroxidase (GPrx), which reduces H2O2 to water, provide evidence that H2O2 is important in 
insulin sensitivity. GPrx-deficient mice are protected against HFD induced insulin resistance (36). H2O2 
and Nox4 may therefore, be components of a complex system of receptor tyrosine kinases/PTPs and 
oxidants that regulate insulin-mediated glucose lowering. Consistent with this hypothesis, we showed that 
the enhanced insulin-stimulated glucose disposal of mIGFREO was blunted by infusion of the H2O2 
degrading enzyme, catalase. Moreover, we show that insulin receptors in liver from mIGFREO treated 
with systemic insulin have increased tyrosine phosphorylation, which is reduced to WT levels by catalase.  
 
A number of mechanisms may underpin endothelial cell release of H2O2 at levels that enhance 
whole body insulin sensitivity in mIGFREO. We have shown increased expression of Nox4 NAD(P)H 
oxidase in endothelial cells from mIGFREO. Nox4 is unique amongst the NADPH oxidases in that it 
generates H2O2 (37) and is constitutively active, generating H2O2 at concentrations proportionate to its 
expression (38). Consistent with this, we have shown that increased endothelial cell expression of Nox4 
leads to increased basal H2O2 release (39). In mIGFREO, as discussed above, this enhances insulin 
sensitivity by redox priming of insulin receptors. Nox4 is also an insulin-responsive enzyme (40). When 
insulin binds to its receptor, it rapidly activates Nox4 to generate a transient burst of H2O2 (33,34). This 
short-lived increment in H2O2 enhances insulin sensitivity by inhibition of PTP1B and PTEN both of 
which are negative regulators of insulin signalling (33). 
 
NADPH oxidase derived oxidants as signalling molecules.  
 
The NADPH oxidases are a group of enzymes whose specific function is to generate superoxide 
(41). Members of the family are named after the transmembrane protein Nox. All 7 Nox proteins share 
highly conserved structural features; despite this, Nox proteins differ in their mode of activation, their 
interaction with the transmembrane protein p22phox and the requirement for additional maturation and 
activation factors (41). Nox4 is highly expressed in human endothelial cells (42) and unlike other Nox 
isoforms, is constitutively active and independent of cytosolic activator proteins or regulatory domains. 
Recent studies demonstrate that H2O2 is the principal oxidant generated by Nox4, rather than O2
˙¯(37). In 
the present report, we identify a previously unidentified pathway, activated in the presence of an 
evolutionarily conserved response to cellular stress i.e. downregulation of insulin and IGF-1 signalling. 


























    
    















DOI: 10.1161/CIRCRESAHA.121.319517   10 
increased generation of the signalling oxidant H2O2, which in turn leads to redox priming of insulin 
receptors in canonical insulin target tissues, enhancing whole body insulin sensitivity and reducing fasting 
free fatty acid levels (See schematic representation in the Graphical Abstract). 
 
mIGFREO mice reveal the microRNA miR-25 as an important transcriptional regulator of Nox4 
that is dysregulated in humans with type 2 diabetes mellitus and advanced atherosclerosis.  
 
Nox4 is thought to be unique amongst the NADPH oxidase isoforms, in that the principal 
mechanism of regulation is transcriptional (43). Amongst a number of potential transcriptional regulators 
of Nox4 expression, the microRNA miR-25 has emerged as potentially important in diabetes (44). mIR-
25 having been shown to negatively regulate Nox4 expression in a number of studies (45,46). miRNAs 
are a class of non-coding RNA that play a critical role in cell differentiation, proliferation and survival by 
binding to complementary target mRNAs, leading to transcriptional inhibition or degradation (47). 
miRNAs are found to be dysregulated in a range of disorders associated with abnormal cellular growth 
and/or metabolism (48). We examined expression of mIR-25 in endothelial cells and whole aorta from 
mIGFREO mice, consistent with increased Nox4 expression, we found mIR-25 to be decreased in both 
aorta and endothelial cells. We, then examined expression of mIR-25 in saphenous vein endothelial cells 
from patients with advanced atherosclerosis and type 2 diabetes, showing increased mIR-25 consistent 
with the reduced Nox4 seen in endothelial cells from these patients. To take this a step further, we 
expressed mutant IGF-1R in saphenous vein endothelial cells from patients with advanced atherosclerosis 
and demonstrated a reduction in mIR-25 expression and an increase in Nox4 expression. Another 
intriguing finding in the present study was the reduced Nox2 in mIGFREO mice. Consistent with our 
findings, studies have shown that Nox4 may inhibit Nox2 expression (49,50). Our dataset raise the 
possibility that by manipulating miR-25, it may be possible to change expression of Nox4 and insulin 
sensitivity at a whole body level. An interesting initial experiment would be to administer miR-25 
mimetic to mIGFREO mice, where the initial proof of concept would be a reduction Nox4 and a 
commensurate decline in whole body insulin sensitivity. 
 
Study limitations.  
 
The Tie-2 promoter has been shown on occasions to drive expression in populations of myeloid 
cells (51), although using a similar approach to generate mice over-expressing the insulin receptor in 
endothelial cells (8), we did not demonstrate significant off-target expression. Consistent with this, we did 
not demonstrate significant expression of mIGF-1R in monocytes from mIGFREO (Online Figure I). 
While one could argue that the changes in glucose tolerance in mIGFREO mice are relatively small, in the 





Here, we show that in the setting of insulin and IGF-1 resistance, the endothelium undergoes a 
phenotypic change underpinned by increased endothelial cell Nox4 NADPH oxidase expression that 
augments H2O2 generation. This H2O2 release is likely to act in a paracrine fashion to enhance insulin-
mediated glucose lowering in skeletal muscle and brown adipose tissue; therefore, revealing novel 
crosstalk between the endothelium and insulin sensitive tissues. Thus, this dataset significantly 
contributes to our understanding of the nature and mechanism of mammalian responses to metabolic 
stress and provides a new perspective in understanding of the regulation of the insulin/IGF-1 pathways 
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Figure 1. Endothelial cells from humans with type 2 diabetes and advanced atherosclerosis are 
resistant to both insulin and IGF-1. (A&B) Unstimulated, basal total eNOS (A; No Diabetes n=5, 
Diabetes n=8) and AKT (B; No Diabetes n=12, Diabetes n=5) expression in saphenous vein endothelial 
cells (SVEC) from patients with and without type 2 diabetes mellitus. (C&D) Serine-phosphorylated 
eNOS (C; No Diabetes n=12, Diabetes n=7) and serine-phosphorylated Akt (D; No Diabetes n=13, 
Diabetes n=7) in SVEC under basal condition. (E) Insulin or IGF-1 stimulated eNOS serine 
phosphorylation (Ins and IGF-1; 100nM, 10 minutes) in SVEC from patients with diabetes (No Diabetes 
n=12, Diabetes n=7). (F) Akt serine-phosphorylation upon insulin (Ins, 100nM; 10 minutes) and IGF-1 
(IGF, 100nM; 10 minutes) treatment in SVEC from patients with and without diabetes (No Diabetes 
n=11, Diabetes n=6). (G) Representative blots for the data showed in E&F. (H&I) Nox4 (H; No Diabetes 
n=7, Diabetes n=5) and Nox2 (I; No Diabetes n=7, Diabetes n=7) expression in SVEC from patients with 
(Diab) or without diabetes (No-Diab) (Representative blots presented on the right of Figure H. (J) Mean 
superoxide level in SVEC from patients with and without diabetes (No Diabetes n=5, Diabetes n=6). All 
SVEC used after isolation were at passage 2 to 5. Data expressed as mean±sem * denotes p<0.05, no 
diabetes vs diabetes in Figures H-J. In Figure E, * denotes p<0.05, Control vs insulin-stimulation in 
patients without diabetes; ** denotes p<0.05, Control vs IGF-1 stimulation in patients without diabetes, # 
denotes p<0.05, insulin-stimulation in diabetes vs without diabetes and ## denotes p<0.05, IGF-1 
stimulation in diabetes vs without diabetes. In Figure F * denotes p<0.05, Control vs insulin-stimulation 
in patients without diabetes; ** denotes p<0.05, Control vs IGF-1 stimulation in patients without diabetes, 
# denotes p<0.05, Control vs insulin-stimulation in diabetes and ## denotes p<0.05, Control vs IGF-1 
stimulation in diabetes.  (‘B’ denotes basal unstimulated cells grown in full growth medium for total 
protein expression. ‘C’ denotes control cells in 0.2% serum-containing medium). Data in A-D and H-J 
were analysed using unpaired Students t test. Others were analysed using one way ANOVA Fisher’s test. 
 
Figure 2. Generation and characterisation of transgenic mice over-expressing mutant IGF-1 
receptor in the endothelium. (A) Body (n=11 each group) and (B) Organ weights of mIGFREO and 
wild type littermate (WT) mice (WT n=5, mIGFREO n=8). (C&D) Mutant human IGF-1R mRNA 
expression in aorta and lungs (C; WT aorta and mIGFREO aorta n=10. WT lungs n=9, mIGFREO lungs 
n=11) in mIGFREO mice and in pulmonary endothelial cells (PEC) and non-endothelial cells (non-PEC, 
described in Methods) (D; WT n=4, mIGFREO n=4).  (E&F) IGF-1 receptor (IGF-1R) expression (E; 
WT n=5, mIGFREO n=6) and hybrid receptor (F; WT n=8, mIGFREO n=5) protein expression in PEC of 
mIGFREO and WT. (G&H) Hybrid receptor activation at insulin receptor IR-pY1334, upon insulin (Ins, 
150nM, 10 min) (G; WT n=5, mIGFREO n=5) and IGF-1 stimulation (IGF-1, 150nM, 10 min) (H; WT 
n=5, mIGFREO n=6) in PEC of mIGFREO and WT. Data expressed as mean±sem. * denotes p<0.05. In 
Figure C - H, * denotes p<0.05, WT vs mIGFREO. Data in A was analysed using 2-way ANOVA, 
followed by Bonferroni's multiple comparisons test, B were analysed by multiple t test, Data in C, D, E 
were analysed by unpaired Students t test with Mann-Whitney comparison, F-H were analysed by 
Unpaired Students t test.  
 
Figure 3. Disrupted insulin and IGF-1 signalling in mIGFREO PEC. (A) Representative blots for 
figures B to E. (B&C) Total Akt (B; WT n=5, mIGFREO n=5) and total eNOS (C; WT n=6, mIGFREO 
n=6) expression in wild type (WT) and mIGFREO pulmonary endothelial cells (PEC). (D&E) Basal 
serine phosphorylated AKT (D; WT n=8, mIGFREO n=7) and serine phosphorylated eNOS (E; WT n=8, 
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denotes mutant human IGF1-R transgenic mice. Data expressed as mean±sem. * denotes p<0.05, WT vs 
mIGFREO. Data in B-E were analysed using Unpaired Students t test.  
 
Figure 4. mIGFREO mice had blunted eNOS phosphorylation while sustained Akt phosphorylation 
in response to insulin or IGF-1. (A) Representative blots for Figures B and C. (B&C) Insulin (Ins, 
150nM, 10 min) and IGF-1 (IGF-1; 150nM, 10 min) stimulated Akt (B; WT n=7, mIGFREO n=7), eNOS 
(C; WT n=6, mIGFREO n=9) serine-phosphorylation in WT and mIGFREO PEC. (D&E) eNOS activity 
in WT and mIGFREO (TG) PEC upon insulin (150nM; 30 min; D; WT n=5, mIGFREO n=7) and IGF-1 
(150nM; 30 min; E; WT n=5, mIGFREO n=7) stimulation. (F) Representative blots for figures G and H. 
(G&H) Dose-dependent response to insulin (Ins; 50, 150nM, 10 min) induced serine-phosphorylation of 
Akt and eNOS in WT endothelial cells (PEC; G; WT n=21, mIGFREO n=22). Dose-dependent response 
to insulin (Ins; 50, 150nM, 10 min) induced serine-phosphorylation of Akt and eNOS in mIGFREO 
endothelial cells (H; WT n=21, mIGFREO n=22). WT denotes wild type mice and mIGFREO / TG 
denotes mutant human IGF1-R transgenic mice. Data expressed as mean±sem. (In Fig B *denotes 
p<0.05, Control vs insulin-stimulated Akt phosphorylation and **denotes p<0.05, Control vs IGF-1-
stimulated Akt phosphorylation in WT littermates, # denotes p<0.05, Control vs insulin-stimulated Akt 
phosphorylation and ## denotes p<0.05, Control vs IGF-1-stimulated Akt phosphorylation in mIGFREO 
cells; In Fig C † denotes p<0.05, Control vs insulin-stimulated eNOS phosphorylation and †† denotes 
p<0.05, Control vs IGF-1-stimulated eNOS phosphorylation in wild type cells. # denotes p<0.05, 
WT+Insulin vs TG+Insulin for eNOS phosphorylation, ## denotes p<0.05 WT+IGF-1 vs TG+IGF-1 for 
eNOS phosphorylation; In Fig D and E * denotes p<0.05, WT Control vs WT+Insulin or WT Control vs 
WT+IGF-1. # denotes p<0.05 WT+Insulin vs TG+Insulin or WT+IGF-1 vs TG+IGF-1; In Fig G and H * 
denotes p<0.05, serine-phosphorylation of Akt or eNOS at 50nmol/L insulin in WT or mIGFREO. # 
denotes p<0.05 serine-phosphorylation of Akt or eNOS at 150nmol/L insulin in WT or mIGFREO). Data 
B-H were analysed using one-way ANOVA, followed by Fisher’s test. 
 
Figure 5. mIGFREO mice have normal glucose olerance but enhanced glucose lowering in 
response to systemic insulin or IGF-1. (A&B) Blood glucose (A; WT n=18, mIGFREO n=18) and 
insulin concentration (B; WT n=5, mIGFREO n=7) in mIGFREO and WT littermates in fasting and fed 
state. (C-G) Glucose tolerance (C; WT n=20, mIGFREO n=22), insulin tolerance (D; WT n=20, 
mIGFREO n=22), area under curve for insulin tolerance tests (E; WT n=20, mIGFREO n=21), IGF-1 
tolerance (F; WT n=16, mIGFREO n=17), and area under the curve for IGF-1 tolerance tests (G; WT 
n=16, mIGFREO n=17) in mIGFREO mice and WT littermates. (H) Insulin-induced vasorelaxation in 2nd 
order mesenteric vessels from WT (n=17) and mIGFREO (n=20). (I) Mean area under curve of the 
vasorelaxation data presented in (H) (J&K) Plasma free fatty acid (J; WT n=16, mIGFREO n=16) and 
triglyceride concentration in mIGFREO and WT littermates (K; WT n=11, mIGFREO n=18). Data 
expressed as mean±sem. * denotes p<0.05, WT vs mIGFREO. Data in A, B, E, G, I were analysed using 
unpaired Students t test. Data in C, D, F were analysed using 2-way ANOVA, followed by Fisher’s test. 
Data in H analysed using -way ANOVA, followed by Bonferroni's multiple comparisons test. Data in J 
and K were analysed using unpaired t test, followed by Mann Whitney test.  
 
Figure 6. Enhanced insulin sensitivity in mIGFREO mice. (A-C) Data from low-dose 
hyperinsulinaemic euglycaemic clamp studies on mIGFREO and wild type (WT) littermates showing 
blood glucose (A), glucose infusion rate (B) and rate of glucose disappearance (Rd; C) during 
hyperinsulinaemic euglycaemic clamp (WT n=8, mIGFREO n=8).  (D-F) Tissue-specific glucose uptake 
into brown adipose tissue (D; WT n=10, mIGFREO n=9), gastrocnemius skeletal muscle (E; WT n=7, 
mIGFREO n=6) and vastus skeletal muscle (F; WT n=8, mIGFREO n=7). (G&H) Insulin (intraperitoneal 
injection; 0.75U/kg; 15 min) stimulated tyrosine phosphorylation of IR (pY-IR) upon) in liver (G; WT 
n=8, mIGFREO n=8) and skeletal muscle (H; WT n=5, mIGFREO n=6). Data expressed as mean±sem. 
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denotes p<0.05 WT vs mIGFREO. Data in Fig A, B were analysed using 2-way ANOVA, followed by 
Bonferroni's multiple comparisons test. All other data were analysed by unpaired Students t test.  
 
Figure 7. Excess generation of hydrogen peroxide in mIGFREO mice. (A&B) Insulin tolerance 
testing after catalase infusion in wild type (WT) (A) and mIGFREO (B) mice (WT n=17, mIGFREO 
n=20). (C) Area under the curve for ITT presented in A&B showing mead data for WT, mIGFREO and 
mIGFREO post-catalase infusion (10,000U/kg/day; 5 days) (WT, n=18, mIGFREO n=21). (D; WT n=12, 
mIGFREO n=12) Tyrosine phosphorylation of IR upon insulin stimulation (Ins, 0.75U/kg; 15 min) with 
and without catalase infusion in liver (n=8; representative blots shown on the right). (E&F) Relative 
mRNA expression of Nox2 (E; WT, n=3, mIGFREO n=4) and Nox4 (F; WT n=6, mIGFREO n=9) in 
endothelial cells of mIGFREO and WT littermates. (G&H) Protein expression of Nox2 (G; WT n=7, 
mIGFREO n=6) and Nox4 (H; WT n=7, mIGFREO n=5) in endothelial cells of mIGFREO and WT 
littermates. Data expressed as mean±sem. In Figure B * denotes p<0.05 mIGFREO vs 
mIGFREO+Catalase. In Figure C, ** denotes p<0.05 mIGFREO vs mIGFREO+Catalase. In Figure D, * 
denotes p<0.05, WT vs mIGFREO; # denotes p<0.05 mIGFREO vs mIGFREO+catalase. In Figure F, G, 
H * denotes p<0.05 WT vs mIGFREO. Data in A and B were analysed using multiple t test. Data in C 
and D were analysed by one-way ANOVA with Fisher’s test. Data in E were analysed using unpaired 
Student t test. All others were analysed using unpaired Student t test, Mann Whitney test. 
 
Figure 8. miR-25 levels in mIGFREO and saphenous vein endothelial cells (SVEC). (A&B) Aortic 
(A; WT n=6, mIGFREO n=9) and PEC (B; WT n=7, mIGFREO n=5) levels of miR-25 mRNA 
expression in mIGFREO and WT littermates (WT). (C) miR-25 mRNA level in SVEC from patients with 
and without diabetes (No Diabetes n=7, Diabetes n=5). (D&E) miR-25 mRNA levels (D; No Diabetes 
n=5, Diabetes n=5) and Nox4 protein (E; WT n=7, mIGFR n=6) levels in SVEC from patients without 
diabetes, transfected with mutant IGF-1 receptor (mIGF-1R) cDNA compared to WT cDNA. (F) Nox4 
mRNA expression in SVEC from patients without diabetes transfected with miR-25 mimetic or 
scrambled control (Scrambled n=5, mimetic n=5). (Graphical Abstract) Schematic representation 
showing conceptual framework for insulin/IGF-1 resistance in endothelial cells leading to decreased miR-
25 and a concomitant increase in Nox4, hydrogen peroxide (H2O2), leading to enhanced whole-body 
insulin sensitivity. Data expressed as mean±sem * denotes p<0.05, WT vs mIGFREO or no diabetes vs 
diabetes or WT-cDNA vs mIGF-1R-cDNA or scrambled vs miR-25 mimetic. Data were analysed using 
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NOVELTY AND SIGNIFICANCE 
 
What Is Known? 
 
 Type 2 diabetes mellitus is characterized by an inability of both insulin and insulin like growth 
factor-1 (IGF-1) to appropriately activate their intracellular signalling networks in the endothelium and 
other tissues. 
 
 The combination of insulin and IGF-1 resistance in skeletal muscle in mice, due to expression of 
a mutant IGF-1 receptor (mIGF-1R) which forms non-functioning hybrids with native insulin (IR) and 
IGF-1 receptors (IGF-1R), leads to type 2 diabetes. 
 
 The effect of the combination of insulin and IGF-1 resistance specific to the endothelium at a 
cellular and systemic level remains unexplored.  
 
What New Information Does This Article Contribute? 
 
 To examine the combination of reduced insulin and IGF-1 sensitivity in endothelial cells (EC), 
we generated transgenic mice expressing mIGF-1R specifically in EC (mIGF-1R endothelium 
overexpressing mice: mIGFREO). 
 
 Despite resistance to insulin and IGF-1, stimulated activation of endothelial nitric oxide synthase 
in EC mIGFREO demonstrated enhanced insulin-stimulated glucose uptake due to redox priming of IR 
by NOX4 NADPH oxidase (NOX4)-derived H2O2. 
 
 The increase in NOX4 in mIGFREO EC was due to a reduction in expression of the inhibitory 
microRNA mIR-25. 
 
Type 2 diabetes mellitus in humans and rodents is associated with whole-body and EC resistance to the 
actions of the closely related hormones insulin and IGF-1. While the effects of reduced insulin or IGF-1 
sensitivity in EC on vascular and systemic metabolic homeostasis are well established, the effect of the 
combination of insulin and IGF-1 resistance in EC on vascular function and glucose homeostasis remains 
unexplored. To examine this question, we generated mIGFREO mice. mIGFREO had enhanced insulin-
mediated glucose lowering, enhanced insulin-induced glucose uptake in muscle and fat and greater 
insulin-mediated vasodilatation of 2nd order mesenteric arteries. This potentially advantageous effect of 
EC specific insulin and IGF-1 resistance was due to redox priming of IR in liver and muscle by NOX4 
derived H2O2. NOX4 activity is dependent on its expression levels, consistent with this we showed 
increased NOX4 expression in mIGFREO EC due to a reduction in expression of the microRNA mIR-25. 
Treating EC from humans with a mIR-25 mimetic reduced, whereas transfection of EC from humans with 
mIGF-1R increased NOX4 expression. Our data reveal a hitherto unrecognized cross talk between EC 
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